第一作者机构:[1]Univ Autonoma Barcelona, Vall dHebron Inst Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
推荐引用方式(GB/T 7714):
Felip E.,Mok T. S. K.,Lu S.,et al.Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12[J].JOURNAL OF THORACIC ONCOLOGY.2024,19(10):S30-S30.
APA:
Felip, E.,Mok, T. S. K.,Lu, S.,Barlesi, F.,Jotte, R....&Duruisseaux, M..(2024).Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12.JOURNAL OF THORACIC ONCOLOGY,19,(10)
MLA:
Felip, E.,et al."Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12".JOURNAL OF THORACIC ONCOLOGY 19..10(2024):S30-S30